Literature DB >> 15054118

Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.

Chun-Yang Xiao1, Min Chen, Zsuzsanna Zsengellér, Csaba Szabó.   

Abstract

Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP)-1 by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury during myocardial infarction. Because diabetes mellitus can substantially alter cellular signal transduction pathways, we have now investigated whether the PARP pathway also contributes to myocardial ischemia/reperfusion (MI/R) injury in diabetes mellitus in rodents. Myocardial ischemia/reperfusion in control and streptozotocin-diabetic rats was induced by transient ligation of the left anterior descending coronary artery. PARP activation was inhibited by the isoindolinone derivative PARP inhibitor INO-1001. In diabetic rats, a more pronounced degree of myocardial contractile dysfunction developed, which also was associated with a larger infarct size, and significant mortality compared with nondiabetic rats. Inhibition of PARP provided a similar degree of myocardial protective effect in diabetic and nondiabetic animals and reduced infarct size and improved myocardial contractility. In diabetic rats, PARP inhibition reduced mortality during the reperfusion phase. There was marked activation of PARP in the ischemic/reperfused myocardium, which was blocked by INO-1001. In addition, there was a significant degree of mitochondrial-to-nuclear translocation of the cell death effector apoptosis-inducing factor (AIF) in myocardial infarction, which was blocked by pharmacological inhibition of PARP. The role of PARP in regulating AIF translocation in myocytes also was confirmed in an isolated perfused heart preparation. Overall, the current results demonstrate the importance of the PARP pathway in diabetic rats subjected to myocardial infarction and demonstrate the role of PARP in regulating AIF translocation in MI/R.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054118     DOI: 10.1124/jpet.104.066803

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Role of apoptosis-inducing factor, proline dehydrogenase, and NADPH oxidase in apoptosis and oxidative stress.

Authors:  Sathish Kumar Natarajan; Donald F Becker
Journal:  Cell Health Cytoskelet       Date:  2012-02-01

2.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

Review 3.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

4.  Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes.

Authors:  Domokos Gerö; Petra Szoleczky; Athanasia Chatzianastasiou; Andreas Papapetropoulos; Csaba Szabo
Journal:  Mol Med       Date:  2014-07-31       Impact factor: 6.354

Review 5.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

Review 6.  Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).

Authors:  Badar Ul Islam; Safia Habib; Parvez Ahmad; Shaziya Allarakha; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2015-01-20

Review 7.  Chromatin remodeling in cardiovascular development and physiology.

Authors:  Pei Han; Calvin T Hang; Jin Yang; Ching-Pin Chang
Journal:  Circ Res       Date:  2011-02-04       Impact factor: 17.367

Review 8.  Molecular mechanisms of cardiomyocyte aging.

Authors:  Anna Sheydina; Daniel R Riordon; Kenneth R Boheler
Journal:  Clin Sci (Lond)       Date:  2011-10       Impact factor: 6.124

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.